8-K Announcements
6Material company update
May 22, 2026·SEC
Material company update
May 15, 2026·SEC
Material company update
May 14, 2026·SEC
VolitionRx Limited(VNRX)Earnings, Financials & Key Ratios
VNRX•AMEX
Price updated Jun 24, 2026
AboutVolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.Show more
- Revenue$2M+40.0%
- EBITDA-$20M+22.1%
- Net Income-$23M+13.4%
- EPS (Diluted)-4.40+29.0%
- Gross Margin100%
- EBITDA Margin-1158.15%+44.4%
- Operating Margin-1228.57%+43.9%
- Net Margin-1352.16%+38.2%
VNRX Key Insights
VolitionRx Limited (VNRX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 164.1%
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 2 (bottom 2%)
- ✗Shares diluted 23.5% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when VNRX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
VNRX Price & Volume
VolitionRx Limited (VNRX) stock price & volume — 10-year historical chart
Loading chart...
VNRX Growth Metrics
VolitionRx Limited (VNRX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years164.15%
3 Years77.98%
TTM88.49%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-2.39%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM22.24%
Return on Capital
10 Years-173.86%
5 Years-263.15%
3 Years-311.79%
Last Year-
VNRX Peer Comparison
VolitionRx Limited (VNRX) competitors in Molecular and Genetic Diagnostics — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 EXAS | 20.02B | 104.91 | -95.37 | 17.69% | -6.4% | -8.66% | 1.05 | |
 ILMN | 26.6B | 175.09 | 32.13 | -0.78% | 19.43% | 32.84% | 0.94 | |
 NTRA | 37.23B | 259.97 | -171.03 | 35.9% | -9.05% | -15.13% | 0.13 | |
 GKOS | 8.06B | 137.76 | -42 | 32.33% | -34.34% | -26.46% | 0.21 | |
 GH | 18.16B | 136.96 | -41.25 | 32.88% | -40.1% | |||
 CDNA | 1.4B | 27.13 | -67.83 | 13.79% | -1.98% | -2.61% | 0.06 | |
 TMDX | 2.68B | 77.62 | 15.94 | 37.13% | 27.04% | 41.92% | 0.99 | |
 BNGO | 3.71M | 1.13 | -0.23 | -7.37% | -109.95% | -71.38% | 0.16 |
Compare VNRX vs Peers
VolitionRx Limited (VNRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
VNRX Income Statement
VolitionRx Limited (VNRX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 17.1K | 13.43K | 90.03K | 306.39K | 775.3K | 1.23M | 1.73M | 2.47M |
Revenue Growth % | - | - | - | -21.43% | 570.25% | 240.3% | 153.04% | 59.1% | 40.04% | 88.49% |
Cost of Goods Sold | 542.48K | 639.92K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 254.41K |
COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
Gross Profit | -542.48K▲ 0% | -639.92K▼ 18.0% | 17.1K▲ 102.7% | 13.43K▼ 21.4% | 90.03K▲ 570.3% | 306.39K▲ 240.3% | 775.3K▲ 153.0% | 1.23M▲ 59.1% | 1.73M▲ 40.0% | 2.21M▲ 0% |
Gross Margin % | - | - | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 89.68% |
Gross Profit Growth % | -75.33% | -17.96% | 102.67% | -21.43% | 570.25% | 240.3% | 153.04% | 59.1% | 40.04% | - |
Operating Expenses | 15.05M | 17.9M | 16.06M | 21.26M | 28.42M | 32.09M | 36.76M | 28.26M | 22.95M | 23.69M |
OpEx % of Revenue | - | - | 93940.22% | 158276.25% | 31568.96% | 10472.36% | 4741.76% | 2290.9% | 1328.57% | - |
Selling, General & Admin | 6.13M | 6.95M | 5.49M | 6.54M | 14.83M | 16.4M | 16.92M | 13.64M | 13.38M | 13.57M |
SG&A % of Revenue | - | - | 32083.77% | 48682.74% | 16467.28% | 5354.14% | 2182.3% | 1105.75% | 774.85% | - |
Research & Development | 8.91M | 10.91M | 10.36M | 14.53M | 13.02M | 15.33M | 19.55M | 14.41M | 10.08M | 10.33M |
R&D % of Revenue | - | - | 60618% | 108195.21% | 14463.72% | 5004.37% | 2521.79% | 1167.93% | 583.62% | - |
Other Operating Expenses | 349.84K | 37.23K | 211.73K | 187.83K | 574.39K | 348.81K | 292.05K | 212.43K | -516.51K | -208.51K |
Operating Income | -15.05M▲ 0% | -17.9M▼ 19.0% | -16.04M▲ 10.4% | -21.25M▼ 32.4% | -28.33M▼ 33.3% | -31.78M▼ 12.2% | -35.99M▼ 13.2% | -27.02M▲ 24.9% | -21.22M▲ 21.5% | -21.48M▲ 0% |
Operating Margin % | - | - | -93840.22% | -158176.25% | -31468.96% | -10372.36% | -4641.76% | -2190.9% | -1228.57% | -870.98% |
Operating Income Growth % | -22.66% | -18.95% | 10.36% | -32.44% | -33.35% | -12.17% | -13.24% | 24.91% | 21.47% | - |
EBITDA | -14.5M | -17.26M | -15.14M | -20.21M | -27.19M | -30.59M | -34.57M | -25.69M | -20.01M | -20.32M |
EBITDA Margin % | - | - | -88561.72% | -150423.9% | -30197.06% | -9983.98% | -4459.48% | -2082.35% | -1158.15% | -823.83% |
EBITDA Growth % | -21.29% | -18.99% | 12.27% | -33.46% | -34.55% | -12.51% | -13.02% | 25.71% | 22.11% | 11.04% |
D&A (Non-Cash Add-back) | 542.48K | 639.92K | 902.41K | 1.04M | 1.15M | 1.19M | 1.41M | 1.34M | 1.22M | 1.16M |
EBIT | -14.7M | -17.9M | -15.97M | -20.27M | -26.83M | -30.43M | -35.46M | -26.92M | -21.01M | -20.98M |
Net Interest Income | 0 | 0 | -14.21K | -80.3K | -153.07K | -47.82K | -128.3K | -330.42K | -2.49M | -2.97M |
Interest Income | 0 | 0 | 112.37K | 49.49K | 2.73K | 125.27K | 93.32K | 9.95K | 600 | 458 |
Interest Expense | 73.13K | 110.92K | 126.57K | 129.8K | 155.8K | 173.09K | 221.62K | 340.36K | 2.49M | 2.97M |
Other Income/Expense | -73.13K | -110.92K | -56.13K | 848.52K | 1.34M | 1.18M | 310.62K | -233.01K | -2.28M | -3.25M |
Pretax Income | -14.77M▲ 0% | -18.01M▼ 21.9% | -16.1M▲ 10.6% | -20.4M▼ 26.7% | -26.99M▼ 32.3% | -30.6M▼ 13.4% | -35.68M▼ 16.6% | -27.26M▲ 23.6% | -23.5M▲ 13.8% | -24.73M▲ 0% |
Pretax Margin % | - | - | -94168.55% | -151859.55% | -29976.99% | -9986.71% | -4601.7% | -2209.79% | -1360.63% | -1002.82% |
Income Tax | -276.71K | 110.92K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 1.87% | -0.62% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -14.77M▲ 0% | -18.01M▼ 21.9% | -16.1M▲ 10.6% | -20.35M▼ 26.4% | -26.81M▼ 31.8% | -30.27M▼ 12.9% | -35.32M▼ 16.7% | -26.97M▲ 23.6% | -23.36M▲ 13.4% | -24.6M▲ 0% |
Net Margin % | - | - | -94168.55% | -151508.34% | -29782.49% | -9879.11% | -4555.53% | -2186.27% | -1352.16% | -997.46% |
Net Income Growth % | -24.06% | -21.93% | 10.6% | -26.42% | -31.75% | -12.88% | -16.68% | 23.65% | 13.39% | -2.39% |
Net Income (Continuing) | -14.77M | -18.01M | -16.1M | -20.4M | -26.99M | -30.6M | -35.68M | -27.26M | -23.5M | -24.73M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | -47.18K | -222.29K | -551.97K | -909.97K | -1.2M | -1.35M | -1.39M |
EPS (Diluted) | -11.20▲ 0% | -11.40▼ 1.8% | -8.20▲ 28.1% | -9.00▼ 9.8% | -10.20▼ 13.3% | -11.00▼ 7.8% | -10.00▲ 9.1% | -6.20▲ 38.0% | -4.40▲ 29.0% | -3.57▲ 0% |
EPS Growth % | -7.69% | -1.79% | 28.07% | -9.76% | -13.33% | -7.84% | 9.09% | 38% | 29.03% | 22.24% |
EPS (Basic) | -11.20 | -11.40 | -8.20 | -9.00 | -10.20 | -11.00 | -10.00 | -6.20 | -4.40 | - |
Diluted Shares Outstanding | 1.32M | 1.57M | 1.96M | 2.26M | 2.63M | 2.77M | 3.56M | 4.33M | 5.34M | 6.88M |
Basic Shares Outstanding | 1.32M | 1.57M | 1.96M | 2.26M | 2.63M | 2.77M | 3.56M | 4.33M | 5.34M | 6.88M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
VNRX Balance Sheet
VolitionRx Limited (VNRX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 10.57M | 13.9M | 17.56M | 20.33M | 21.98M | 12.17M | 21.85M | 4.06M | 2.06M | 4.52M |
Cash & Short-Term Investments | 10.12M | 13.43M | 16.97M | 19.44M | 20.58M | 10.87M | 20.73M | 3.26M | 1.12M | 3.1M |
Cash Only | 10.12M | 13.43M | 16.97M | 19.44M | 20.58M | 10.87M | 20.73M | 3.26M | 1.12M | 3.1M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 0 | 0 | 7.12K | 12.51K | 72.61K | 242.62K | 110.57K | 317.81K | 252.24K |
Days Sales Outstanding | - | - | - | 193.41 | 50.72 | 86.5 | 114.22 | 32.72 | 67.15 | 39.55 |
Inventory | 0 | 0 | 0 | 0 | 598.37K | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 202.29K | 229.75K | 322.59K | 576.66K | 786.64K | 447.57K | 360.13K | 343.14K | 626.09K | 291.19K |
Total Non-Current Assets | 4.06M | 3.59M | 3.74M | 5.82M | 5.51M | 6.12M | 6.1M | 5.34M | 4.84M | 4.52M |
Property, Plant & Equipment | 3.48M | 3.12M | 3.36M | 5.5M | 5.29M | 6.01M | 6.07M | 5.03M | 4.52M | 4.2M |
Fixed Asset Turnover | - | - | 0.01x | 0.00x | 0.02x | 0.05x | 0.13x | 0.25x | 0.38x | 0.53x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 576.4K | 466.9K | 372.31K | 321.64K | 216.88K | 110.5K | 23.89K | 313.75K | 316.7K | 318.9K |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Assets | 14.62M▲ 0% | 17.49M▲ 19.6% | 21.29M▲ 21.7% | 26.15M▲ 22.8% | 27.49M▲ 5.1% | 18.3M▼ 33.4% | 27.95M▲ 52.8% | 9.4M▼ 66.4% | 6.9M▼ 26.6% | 9.04M▲ 0% |
Asset Turnover | - | - | 0.00x | 0.00x | 0.00x | 0.02x | 0.03x | 0.13x | 0.25x | 0.32x |
Asset Growth % | -40.87% | 19.59% | 21.74% | 22.82% | 5.12% | -33.45% | 52.78% | -66.37% | -26.58% | -103.05% |
Total Current Liabilities | 2.29M | 2.33M | 3.86M | 6.24M | 6.52M | 17.39M | 8.94M | 7.79M | 12.23M | 13.85M |
Accounts Payable | 351.74K | 807.16K | 627.25K | 1.54M | 1.54M | 3.04M | 3.21M | 2.77M | 2.92M | 3.72M |
Days Payables Outstanding | 236.66 | 460.39 | - | - | - | - | - | - | - | 4.34K |
Short-Term Debt | 582.99K | 561.7K | 647.57K | 841.32K | 797.86K | 1.07M | 1.21M | 860.22K | 3.31M | 4.26M |
Deferred Revenue (Current) | 0 | 40.09K | 39.3K | 69.22K | 12.51K | 10M | 106.6K | 230K | 353.85K | 1.18M |
Other Current Liabilities | -139.08K | -145.15K | -39.3K | -69.22K | 0 | 0 | 126.65K | 97.89K | 5.15M | 1.34M |
Current Ratio | 4.61x | 5.96x | 4.55x | 3.26x | 3.37x | 0.70x | 2.44x | 0.52x | 0.17x | 0.33x |
Quick Ratio | 4.61x | 5.96x | 4.55x | 3.26x | 3.28x | 0.70x | 2.44x | 0.52x | 0.17x | 0.33x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | -4.3K |
Total Non-Current Liabilities | 2.38M | 3.02M | 3.23M | 3.62M | 3.25M | 4.04M | 27.72M | 27.72M | 30.26M | 28.55M |
Long-Term Debt | 1.31M | 2.7M | 2.2M | 2.61M | 2.27M | 2.78M | 3.62M | 3.95M | 7.26M | 6.35M |
Capital Lease Obligations | 874.68K | 720.01K | 739.58K | 753.79K | 728.39K | 836.22K | 778.08K | 739.02K | 594.42K | 2.55M |
Deferred Tax Liabilities | -188.58K | -311.04K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | -408.97K | 0 | 0 | 253.22K | 420.47K | 422.71K | 361.24K | 473.65K | 464.93K |
Total Liabilities | 4.67M | 5.35M | 7.09M | 9.86M | 9.77M | 21.42M | 36.66M | 35.51M | 42.49M | 42.4M |
Total Debt | 2.77M | 3.27M | 3.94M | 4.44M | 4.02M | 4.97M | 5.86M | 5.82M | 11.46M | 11.42M |
Net Debt | -7.35M | -10.16M | -13.03M | -15M | -16.56M | -5.89M | -14.87M | 2.56M | 10.35M | 8.32M |
Debt / Equity | 0.28x | 0.27x | 0.28x | 0.27x | 0.23x | - | - | - | - | -0.34x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.56x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.41x |
Interest Coverage | -200.95x | -161.35x | -126.19x | -156.16x | -172.23x | -175.78x | -159.98x | -79.09x | -8.44x | -7.07x |
Total Equity | 9.96M▲ 0% | 12.14M▲ 21.9% | 14.2M▲ 17.0% | 16.29M▲ 14.8% | 17.72M▲ 8.8% | -3.13M▼ 117.6% | -8.71M▼ 178.6% | -26.11M▼ 199.7% | -35.59M▼ 36.3% | -33.36M▲ 0% |
Equity Growth % | -52.97% | 21.92% | 16.95% | 14.76% | 8.77% | -117.64% | -178.62% | -199.67% | -36.33% | -154.59% |
Book Value per Share | 7.55 | 7.74 | 7.25 | 7.20 | 6.73 | -1.13 | -2.45 | -6.03 | -6.66 | -4.85 |
Total Shareholders' Equity | 9.96M | 12.14M | 14.2M | 16.34M | 17.94M | -2.57M | -7.8M | -24.91M | -34.25M | -31.97M |
Common Stock | 26.52K | 35.34K | 41.13K | 48.61K | 53.77K | 57.87K | 81.9K | 96.1K | 125.78K | 7.93K |
Retained Earnings | -55.71M | -73.72M | -89.82M | -110.17M | -136.99M | -167.26M | -202.58M | -229.54M | -252.9M | -259.57M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -129.34K | 223.65K | 125.67K | -59.98K | 148.33K | 227.1K | 243.94K | 385.63K | -295.07K | -160.76K |
Minority Interest | 0 | 0 | 0 | -47.18K | -222.29K | -551.97K | -909.97K | -1.2M | -1.35M | -1.39M |
VNRX Cash Flow Statement
VolitionRx Limited (VNRX) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -12.19M | -14.73M | -12.74M | -16.46M | -20.85M | -15.28M | -18.06M | -25.89M | -19.68M | -20.51M |
Operating CF Margin % | - | - | -74517.17% | -122565.65% | -23162.01% | -4986.34% | -2329.8% | -2099.18% | -1139.49% | - |
Operating CF Growth % | -34.65% | -20.83% | 13.53% | -29.24% | -26.66% | 26.74% | -18.23% | -43.35% | 23.98% | 18.54% |
Net Income | -14.77M | -18.01M | -16.1M | -20.4M | -26.99M | -30.6M | -35.68M | -27.26M | -23.36M | -24.6M |
Depreciation & Amortization | 528.17K | 636.38K | 902.41K | 1.04M | 1.15M | 1.19M | 1.41M | 1.34M | 1.22M | 1.16M |
Stock-Based Compensation | 2.44M | 2.57M | 1.46M | 1.73M | 5.12M | 3.11M | 2.29M | 1.27M | 1.74M | 904.15K |
Deferred Taxes | 38.94K | 403 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 54.51K | 22.78K | 205.46K | -293.31K | 26.17K | 0 | -224.47K | 5.97K | 1.6M | 3.85M |
Working Capital Changes | -480.74K | 45.94K | 793.12K | 1.46M | -156.11K | 11.02M | 14.14M | -1.25M | -885.8K | -1.72M |
Change in Receivables | 0 | 0 | 0 | -7.12K | -12.51K | -72.61K | -169.67K | 132.04K | -207.23K | -63.24K |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -339.66K | 65.84K | 1.11M | 2.05M | 522.22K | 548.61K | 1.22M | -1.22M | 77.98K | 559.61K |
Cash from Investing | -1.43M | -301.81K | -511.27K | -1.65M | -973.56K | -1.57M | -1.08M | -573.85K | -89.56K | -95.79K |
Capital Expenditures | -1.43M | -301.81K | -511.27K | -1.94M | -973.56K | -1.57M | -1.08M | -277.5K | -89.56K | -95.79K |
CapEx % of Revenue | - | - | 2990.56% | 14449.94% | 1081.31% | 512.47% | 139.78% | 22.5% | 5.18% | 3.88% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 293.31K | 0 | 0 | 0 | -296.35K | 0 | 0 |
Cash from Financing | 1.97M | 17.97M | 16.93M | 20.62M | 22.86M | 6.94M | 28.98M | 8.66M | 17.09M | 20.9M |
Debt Issued (Net) | 1.01M | 585.54K | 344.99K | -296.34K | -221.51K | 209.28K | 827.08K | 233.23K | 6.02M | 7.07M |
Equity Issued (Net) | 998.41K | 17.25M | 16.59M | 21.14M | 23.22M | 6.74M | 28.36M | 8.59M | 11.17M | 13.92M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | -54.43K | 0 | 0 | -31.77K | 0 | 0 | 0 |
Other Financing | -45.42K | 136.2K | -6.54K | -224.92K | -140.58K | -7.69K | -200.66K | -168.15K | -98.99K | -89.59K |
Net Change in Cash | -11.56M▲ 0% | 3.31M▲ 128.6% | 3.54M▲ 6.9% | 2.48M▼ 30.0% | 1.14M▼ 54.1% | -9.71M▼ 954.7% | 9.86M▲ 201.5% | -17.47M▼ 277.1% | -2.15M▲ 87.7% | 502.48K▲ 0% |
Free Cash Flow | -13.62M▲ 0% | -15.03M▼ 10.4% | -13.25M▲ 11.9% | -18.41M▼ 38.9% | -21.83M▼ 18.6% | -16.85M▲ 22.8% | -19.15M▼ 13.6% | -26.47M▼ 38.2% | -19.77M▲ 25.3% | -20.6M▲ 0% |
FCF Margin % | - | - | -77507.73% | -137015.59% | -24243.33% | -5498.81% | -2469.59% | -2145.7% | -1144.67% | -835.49% |
FCF Growth % | -43.79% | -10.4% | 11.87% | -38.9% | -18.59% | 22.81% | -13.64% | -38.23% | 25.29% | 7.8% |
FCF per Share | -10.32 | -9.58 | -6.76 | -8.13 | -8.29 | -6.09 | -5.38 | -6.12 | -3.70 | -2.99 |
FCF Conversion (FCF/Net Income) | 0.83x | 0.82x | 0.79x | 0.81x | 0.78x | 0.50x | 0.51x | 0.96x | 0.84x | 0.84x |
Interest Paid | 73.13K | 110.92K | 126.85K | 129.8K | 155.8K | 173.11K | 221.62K | 340.36K | 0 | 123.36K |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
VNRX Key Ratios
VolitionRx Limited (VNRX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -94.88% | -162.99% | -122.24% | -133.49% | -157.66% | -414.78% | - | - | - | 71.3% |
Return on Invested Capital (ROIC) | -630.42% | -584.73% | -764.14% | -1295.31% | -1735.77% | - | - | - | - | 64.71% |
Gross Margin | - | - | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 89.68% |
Net Margin | - | - | -94168.55% | -151508.34% | -29782.49% | -9879.11% | -4555.53% | -2186.27% | -1352.16% | -997.46% |
Debt / Equity | 0.28x | 0.27x | 0.28x | 0.27x | 0.23x | - | - | - | - | -0.34x |
Interest Coverage | -200.95x | -161.35x | -126.19x | -156.16x | -172.23x | -175.78x | -159.98x | -79.09x | -8.44x | -7.07x |
FCF Conversion | 0.83x | 0.82x | 0.79x | 0.81x | 0.78x | 0.50x | 0.51x | 0.96x | 0.84x | 0.84x |
Revenue Growth | - | - | - | -21.43% | 570.25% | 240.3% | 153.04% | 59.1% | 40.04% | 88.49% |
Related:VNRX Dividend History·VNRX Revenue History·VNRX Price History·VNRX P/E History·VNRX Financial Ratios·VNRX Institutional Holders
VNRX SEC Filings & Documents
VolitionRx Limited (VNRX) SEC filings — annual & quarterly reports (10-K, 10-Q)
VNRX Frequently Asked Questions
VolitionRx Limited (VNRX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
VolitionRx Limited (VNRX) reported $2.5M in revenue for fiscal year 2025.
VolitionRx Limited (VNRX) grew revenue by 40.0% over the past year. This is strong growth.
VolitionRx Limited (VNRX) reported a net loss of $24.6M for fiscal year 2025.
Dividend & Returns
VolitionRx Limited (VNRX) had negative free cash flow of $20.6M in fiscal year 2025, likely due to heavy capital investments.